Your first 90 days
Your first 90 days on Zavesca for Gaucher disease
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Zavesca is a capsule taken by mouth, so there are no infusions to book. The first 90 days are mostly about three things the label names: a nerve exam before you start, stomach and bowel side effects, and hand tremor. This page lays out that stretch from the FDA label, the Zavesca site and one insurer's written rules. Generic miglustat capsules also exist, and the insurer policy shown here asks for the generic before the brand.
What has to happen before the first bottle ships
Zavesca has no REMS, so the first fill waits on a nerve exam, a dose set for your kidney function, an insurance approval and a specialty pharmacy shipment. These are the 7 things in the way, in order.
A doctor who knows Gaucher disease
The label says treatment should be directed by physicians who are knowledgeable in the management of Gaucher disease.
- The Cigna policy below asks for a specialist as well.FDA label
A reason enzyme replacement is not an option
Zavesca is approved only for adults for whom enzyme replacement therapy is not a therapeutic option.
- The label gives allergy, hypersensitivity and poor vein access as examples.FDA label
A nerve exam before the first dose
The label says everyone taking Zavesca should have a neurological evaluation at baseline.
- It is repeated about every 6 months during treatment.FDA label
Your kidney function
The label sets a lower starting dose for mild or moderate kidney impairment.
- It does not recommend Zavesca for severe kidney impairment, so tell your doctor about any kidney problems.FDA label
A talk about pregnancy and breastfeeding
The label says Zavesca may harm an unborn baby, based on animal studies.
- It also says breastfeeding is not recommended during treatment.FDA label
The insurance approval
The Cigna policy shown below requires prior authorization.
- It asks for a lab or genetic test confirming Gaucher disease, and it asks for generic miglustat before brand Zavesca.Cigna policy
A specialty pharmacy
Zavesca's site says it is not available at your local pharmacy.
- Accredo, a specialty pharmacy, can ship it to you at the direction of your doctor.Zavesca patient resources
The days that matter
Counted from the first capsule, with refills based on a 90 capsule carton at the full dose of 3 capsules a day. A lower dose makes each carton last longer. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Nerve exam and kidney check
Your doctor does a baseline neurological evaluation, which the label asks for in every patient.
- Kidney function decides whether you start at 3, 2 or 1 capsule a day.
Approval, then the pharmacy ships
Zavesca's site says Accredo, a specialty pharmacy, can ship it to you at the direction of your doctor.
- No source sets how long approval takes, because each insurer works on its own timeline.
First capsule
The labeled dose is one 100mg capsule 3 times a day at regular intervals.
- Zavesca's site gives waking, early afternoon and bedtime as an example, as close to 8 hours apart as possible.
Diarrhea and diet
About 85% of people in studies had diarrhea, and it decreased over time with continued treatment.
- The label says it may respond to diet changes, taking Zavesca between meals or an anti-diarrheal medicine.
End of the first month, the tremor window
About 30% of people in studies reported a hand tremor or a worse existing tremor.
- The label says it usually began within the first month.
First refill
A carton holds 90 capsules, which is 30 days at 3 capsules a day.
- Zavesca's site says the specialty pharmacy calls each month to confirm delivery and arrange your refill.
Second refill
In many cases, tremor resolved between 1 and 3 months during treatment.
- If it continues, the label says the doctor may lower the dose, or stop Zavesca if that does not help within days.
Day 90
The label recommends monitoring platelet counts in people with type 1 Gaucher disease.
- Weight loss, seen in up to 65% of people in studies, was most evident in the first 12 months.
Repeat nerve exam
The label asks for a repeat neurological evaluation about every 6 months.
- Peripheral neuropathy, a nerve problem in the hands or feet, was reported in 3% of Gaucher patients in clinical trials.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Zavesca label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated April 20, 2023, read from the FDA's label database today. FDA label
- April 2023
DailyMed posted version 19 of the label. Its prescribing information still carries a revision date of August 2022, and it lists no recent major changes.FDA label
- December 2020
The FDA approved updated pregnancy and breastfeeding sections in the newer labeling format. The label says Zavesca may cause fetal harm based on animal data, and that breastfeeding is not recommended.FDA letter
- June 2019
The FDA approved a revised carton and blister card that print the generic name in tall man lettering, as migLUstat.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The labeled dose
One 100mg capsule 3 times a day at regular intervals is the recommended dose for adults.
- The patient leaflet says to take it at the same time each day, exactly as prescribed.FDA label
- A lower dose for side effects
The label says it may be necessary to reduce the dose to one 100mg capsule once or twice a day in some people because of tremor or diarrhea.
- Your doctor decides.FDA label
- A lower starting dose for kidney impairment
For mild impairment (creatinine clearance 50 to 70mL/min/1.73m²) the label starts at 100mg twice a day.
- For moderate impairment (30 to 50) it starts at 100mg once a day.FDA label
- Severe kidney impairment
The label does not recommend Zavesca when creatinine clearance is below 30mL/min/1.73m².
- The drug leaves the body mostly through the kidneys.FDA label
- If you miss a dose
The patient leaflet says to skip the missed dose.
- It says to take the next capsule at the usual time.FDA label
- Food and diarrhea
The label says people who have diarrhea may be told to avoid foods high in carbohydrates.
- Diarrhea may also respond to taking Zavesca between meals or to an anti-diarrheal medicine.FDA label
- The diet guide
The Healthy Choices guide on Zavesca's site suggests reducing sugars such as sucrose, lactose and maltose while your body adjusts.
- It says to consult your doctor or a dietitian before changing your diet.Healthy Choices guide
- Used alone
Zavesca is approved as monotherapy, which means on its own and not with another Gaucher medicine.
- The label notes it may increase how fast the body clears imiglucerase (Cerezyme).FDA label
- Pregnancy
The label says Zavesca may harm an unborn baby, based on animal studies.
- The patient leaflet says to tell your healthcare provider right away if you become pregnant or think you may be.FDA label
- Breastfeeding
The patient leaflet says not to breastfeed during treatment with Zavesca.
- It is not known whether the drug passes into breast milk.FDA label
- Male fertility
In a small study, 7 healthy men took miglustat for 6 weeks with no sign of an effect on fertility.
- In male rats it lowered fertility, and the label says the findings were reversible.FDA label
- Adults only
The label says safety and effectiveness in children have not been established.
- The patient leaflet says it is not known if Zavesca is safe and effective under age 18.FDA label
- Storage
Store Zavesca at room temperature, 68°F to 77°F (20°C to 25°C).
- The carton is not child resistant, so keep it out of the reach of children.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Numbness, tingling, pain or burning in your hands or feet
These can be signs of peripheral neuropathy, the most common serious side effect in the trials.
- The patient leaflet says to call your healthcare provider right away.FDA label
New or worse hand tremors
Tremors are common and may begin within the first month.
- The leaflet says to call your healthcare provider right away, who may lower your dose or stop Zavesca.FDA label
Diarrhea
Diarrhea is common with Zavesca and sometimes can be serious.
- The leaflet says to talk with your healthcare provider about your diet, and that an anti-diarrheal medicine may be prescribed.FDA label
Weight loss
Weight loss is common with Zavesca and sometimes can be serious.
- The leaflet says you may lose weight when you start treatment.FDA label
Low platelet count
The leaflet says a low platelet count is common and can be serious.
- Your healthcare provider may do blood tests to monitor your platelet count during treatment.FDA label
Stomach or bowel problems that do not settle
If these continue and do not respond to usual steps such as diet changes, the label says the doctor should check for an underlying bowel disease.FDA label
Other common side effects
The leaflet lists stomach pain, gas, nausea and vomiting, headache, leg and muscle cramps, dizziness, weakness, vision problems, back pain, constipation, dry mouth, memory loss and unsteady walking, among others.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedThe Cigna policy below asks for a report showing low enzyme activity in white blood cells or skin cells, or a genetic test showing changes in both GBA genes.Cigna policy
- The plan wants generic miglustat firstFor brand Zavesca, Cigna asks that the generic be tried first. It then asks that an inactive ingredient difference would cause a significant allergy or serious reaction, per the prescriber.Cigna policy
- The doctor is not a specialistCigna asks that miglustat be prescribed by, or with advice from, a geneticist, endocrinologist, metabolic disorder specialist or a physician who specializes in Gaucher disease.Cigna policy
- The request mentions brain or nerve symptomsCigna does not approve miglustat for Gaucher disease when it is used to manage neurological symptoms such as seizures or abnormal eye movement.Cigna policy
- Also taking another Gaucher medicineCigna treats miglustat used together with Cerezyme, Elelyso, Vpriv or Cerdelga as not medically necessary. The label also approves Zavesca only as monotherapy.Cigna policy
- The local pharmacy cannot fill itZavesca's site says it is not available at your local pharmacy. Accredo, a specialty pharmacy, can ship it at the direction of your doctor.Zavesca patient resources
- A copay you cannot payZavesca's site names no copay card or free drug program. Its contact page lists Janssen at 1-800-526-7736.Zavesca contact page
Cigna prior authorization policy, July 15, 2026
- Gaucher disease type 1, confirmed by one documented test
- The test shows low beta-glucocerebrosidase activity in white blood cells or skin cells, or disease-causing variants in both GBA genes
- Not used to manage neurological symptoms, such as abnormal eye movement, hearing loss, thinking problems or seizures
- Prescribed by, or with advice from, a geneticist, endocrinologist, metabolic disorder specialist or a physician who specializes in Gaucher disease or related disorders
- For brand Zavesca, generic miglustat was tried and cannot be taken because of an inactive ingredient difference that would cause a significant allergy or serious adverse reaction
- Not used together with Cerezyme, Elelyso, Vpriv or Cerdelga
Approval length. One year.
This policy (Drug Coverage Policy IP0446) covers generic miglustat, Yargesa and Zavesca, and it cites the August 2022 Zavesca label, the current text. In 2024 Cigna removed its criteria on age, use alone and whether enzyme replacement is possible, although the label still limits Zavesca to adults who cannot use enzyme replacement. It is here as an example of what a plan asks for, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- Zavesca's contact page lists this number, 1-800-Janssen, and the label gives it for more information and for reporting side effects
- Accredo, a specialty pharmacy, can ship Zavesca at the direction of your doctor. The specialty pharmacy calls each month to confirm delivery and arrange the refill Zavesca patient resources
- A Healthy Choices guide on managing diet while taking Zavesca, free to download Healthy Choices guide
- Zavesca's patient pages name no copay card, bridge supply or free drug program Zavesca patient resources
- For more help, Zavesca's site points to the National Gaucher Foundation at 1-800-504-3189 About Zavesca
Details as the drugmaker publishes them. Zavesca contact page
Five questions for the pharmacist or the support line
- Is this brand Zavesca or generic miglustat, and which one does my plan cover?
- How many capsules a day is my prescription, and how long will one carton last?
- When will you call about my refill, and what number will the call come from?
- What should I do if a shipment is late and I am running low?
- Does my doctor want me to take the capsules between meals?
- Which anti-diarrheal medicine, if any, did my doctor approve for me?
Questions people ask in the first weeks
How is Zavesca taken?
The labeled dose is one 100mg capsule 3 times a day at regular intervals. The label lets the doctor reduce it to once or twice a day because of tremor or diarrhea.
Who can take Zavesca?
The label covers adults with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not an option. Examples in the label are allergy, hypersensitivity and poor vein access.
Does Zavesca have a boxed warning or a REMS?
No. The label has no boxed warning, no REMS safety program and no contraindications. Its warnings cover peripheral neuropathy, tremor, diarrhea and weight loss, and lower platelet counts.
How common is diarrhea on Zavesca?
About 85% of people in clinical studies had diarrhea, according to the label. It decreased over time with continued treatment. The label lists diet changes, taking Zavesca between meals and anti-diarrheal medicines as options.
Will Zavesca cause a tremor?
About 30% of people in studies reported a hand tremor or a worse existing tremor. It usually began within the first month and in many cases resolved between 1 and 3 months.
Why do I need nerve exams on Zavesca?
Peripheral neuropathy was reported in 3% of Gaucher patients in clinical trials. The label asks for a neurological evaluation before treatment and about every 6 months after.
Is there a generic for Zavesca?
Yes. The Cigna policy on this page covers generic miglustat capsules and Yargesa, which it lists as a generic, alongside Zavesca. That policy asks for the generic before brand Zavesca.
Can I take Zavesca if I am pregnant or breastfeeding?
The label says Zavesca may harm an unborn baby, based on animal studies, and that breastfeeding is not recommended. Tell your healthcare provider right away about a known or suspected pregnancy.
Where do I get Zavesca?
Zavesca's site says it is not available at your local pharmacy. Accredo, a specialty pharmacy, can ship it at your doctor's direction. The site says the specialty pharmacy calls each month to arrange the refill.
Free email alert
Hear when the Zavesca label changes
One email the day the FDA revises the Zavesca label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Zavesca only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Gaucher disease for new trials, FDA decisions and label changes for every treatment.
Sources
- Label: ZAVESCA- miglustat capsule (updated April 20, 2023, SPL version 19, prescribing information revised 8/2022), Actelion Pharmaceuticals US, Inc., via DailyMed, April 20, 2023.
- ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease, Patient Resources page, Johnson & Johnson (Actelion Pharmaceuticals US, Inc.), November 1, 2026.
- About - ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease, Johnson & Johnson (Actelion Pharmaceuticals US, Inc.), November 1, 2026.
- ZAVESCA® (miglustat): For the treatment of type 1 Gaucher Disease, Contact us page, Johnson & Johnson (Actelion Pharmaceuticals US, Inc.), November 1, 2026.
- Healthy Choices (ZAVESCA patient brochure, cp-115038v3, 06/25), Johnson & Johnson, June 1, 2025.
- Gaucher Disease - Substrate Reduction Therapy - Miglustat, Drug Coverage Policy IP0446, Cigna, July 15, 2026.
- NDA 021348/S-016 supplement approval letter, Pregnancy and Lactation Labeling Rule updates to the Prescribing Information and Patient Information, FDA, December 8, 2020.
- NDA 021348/S-15 supplement approval letter, Tallman lettering on the carton and foil blister pack, FDA, June 26, 2019.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing geneticist. Found an error? Use the report link in the footer and it will be checked against the source.